Heparanase and hepatocellular carcinoma: Promoter or inhibitor?

被引:15
|
作者
Dong, Shuo [1 ]
Wu, Xiong-Zhi [1 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Zhong Shan Men In Patient Dept, Tianjin 300171, Peoples R China
基金
中国国家自然科学基金;
关键词
Apoptosis; Heparanase; Heparan sulphate; Hepatocellular carcinoma; Infection; Metastasis; FIBROBLAST-GROWTH-FACTOR; HEPATITIS-C VIRUS; MESSENGER-RNA EXPRESSION; ENVELOPE GLYCOPROTEIN E2; ACTIVATED PROTEIN-KINASE; SULFATE PROTEOGLYCANS; TUMOR-GROWTH; QUANTITATIVE-ANALYSIS; CANCER PROGRESSION; GENE-EXPRESSION;
D O I
10.3748/wjg.v16.i3.306
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Heparan sulphate proteoglycans (HSPGs) consist of a core protein and several heparan sulphate (HS) side chains covalently linked. HS also binds a great deal of growth factors, chemokines, cytokines and enzymes to the extracellular matrix and cell surface. Heparanase can specially cleave HS side chains from HSPGs. There are a lot of conflicting reports about the role of heparanase in hepatocellular carcinoma (HCC). Heparanase is involved in hepatitis B virus infection and hepatitis C virus infection, the activation of signal pathways, metastasis and apoptosis of HCC. Heparanase is synthesized as an inactive precursor within late endosomes and lysosomes. Then heparanase undergoes proteolytic cleavage to form an active enzyme in lysosomes. Active heparanase translocates to the nucleus, cell surface or extracellular matrix. Different locations of heparanase may exert different activities on tumor progression. Furthermore, enzymatic activities and non-enzymatic activities of heparanase may play different roles during HCC development. The expression level of heparanase may also contribute to the discrepant effects of heparanase. Growth promoting as well as growth inhibiting sequences are contained within the tumor cell surface heparan sulfate. Degrading different HSPGs by heparanase may play different roles in HCC. Systemic studies examining the processing, expression, localization and function of heparanase should shed a light on the role of heparanase in HCC. (C) 2010 Baishideng. All rights reserved.
引用
收藏
页码:306 / 311
页数:6
相关论文
共 50 条
  • [21] Relationship Between Serum Heparanase and Microscopic Venous Invasion in Patients With Hepatocellular Carcinoma
    Wang, Gui-Bo
    Zhou, Xin-Yu
    Wang, Xiao-Qin
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 134 (02) : 242 - 248
  • [22] mTOR Inhibitor for the Treatment of Hepatocellular Carcinoma
    Kudo, Masatoshi
    DIGESTIVE DISEASES, 2011, 29 (03) : 310 - 315
  • [23] The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma
    El-Assal, ON
    Yamanoi, A
    Ono, T
    Kohno, H
    Nagasue, N
    CLINICAL CANCER RESEARCH, 2001, 7 (05) : 1299 - 1305
  • [24] Heparanase induces necroptosis of microvascular endothelial cells to promote the metastasis of hepatocellular carcinoma
    Xiaopeng Chen
    Bin Cheng
    Dafei Dai
    Yuhai Wu
    Zhiwen Feng
    Chaogang Tong
    Xiangming Wang
    Jun Zhao
    Cell Death Discovery, 7
  • [25] Downregulating the expression of heparanase inhibits the invasion, angiogenesis and metastasis of human hepatocellular carcinoma
    Zhang, Youlei
    Li, Li
    Wang, Yi
    Zhang, Jun
    Wei, Gongtian
    Sun, Yanfu
    Shen, Feng
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 358 (01) : 124 - 129
  • [26] Heparanase: A Dynamic Promoter of Myeloma Progression
    Purushothaman, Anurag
    Sanderson, Ralph D.
    HEPARANASE: FROM BASIC RESEARCH TO CLINICAL APPLICATIONS, 2020, 1221 : 331 - 349
  • [27] Suramin inhibits hepatic tissue damage in hepatocellular carcinoma through deactivation of heparanase enzyme
    Tayel, Ahmed
    Abd El Galil, Khaled H.
    Ebrahim, Mohamed A.
    Ibrahim, Ahmed S.
    El-Gayar, Amal M.
    Al-Gayyar, Mohammed M. H.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 728 : 151 - 160
  • [28] Polymorphisms in the VEGFA promoter are associated with susceptibility to hepatocellular carcinoma by altering promoter activity
    Wu, Xiaopan
    Xin, Zhenhui
    Zhang, Wei
    Wu, Jia
    Chen, Kangmei
    Wang, Huifen
    Zhu, Xilin
    Pan, Liping
    Li, Zhuo
    Li, Hui
    Liu, Ying
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (05) : 1085 - 1093
  • [29] Claudin-1 as a promoter of EMT in hepatocellular carcinoma
    Stebbing, J.
    Filipovic, A.
    Giamas, G.
    ONCOGENE, 2013, 32 (41) : 4871 - 4872
  • [30] SYNTHESIS OF A POTENTIAL HEPARANASE INHIBITOR
    TAKAHASHI, S
    KUZUHARA, H
    CHEMISTRY LETTERS, 1994, (11) : 2119 - 2122